You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsing forms of Multiple Sclerosis

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsing Multiple Sclerosis (RMS) Trial in United States (Ublituximab, Teriflunomide, Oral Placebo)

Completed
Has Results
  • Relapsing Multiple Sclerosis (RMS)
  • Ublituximab
  • +3 more
  • Carlsbad, California
  • +13 more
Nov 5, 2021

Multiple Sclerosis, Relapsing-Remitting Trial in Verona, Lørenskog (GSK1223249, Saline )

Terminated
  • Multiple Sclerosis, Relapsing-Remitting
  • Verona, Veneto, Italy
  • +1 more
Nov 20, 2020

Relapsing Remitting Multiple Sclerosis Trial (PIPE-307 Dose A, PIPE-307 Dose B, Placebo)

Not yet recruiting
  • Relapsing Remitting Multiple Sclerosis
  • PIPE-307 Dose A
  • +2 more
  • (no location specified)
Oct 9, 2023

Relapsing-remitting Multiple Sclerosis Trial (CT-P53, US-Ocrevus, EU-Ocrevus)

Not yet recruiting
  • Relapsing-remitting Multiple Sclerosis
  • CT-P53
  • +2 more
  • (no location specified)
Jun 7, 2023

Multiple Sclerosis Trial in Montpellier (Magnetic Resonance Imaging, Blood withdrawal, Neuropsychological tests)

Not yet recruiting
  • Multiple Sclerosis
  • Magnetic Resonance Imaging
  • +2 more
  • Montpellier, France
    Neurology Department, Hopital Gui de Chauliac
Jul 18, 2023

Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in United

Recruiting
  • Relapsing Multiple Sclerosis
  • +2 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • Best Available Therapy (BAT)
  • Palo Alto, California
  • +20 more
Jan 25, 2023

Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting Trial in Saint Louis (Cladribine)

Recruiting
  • Multiple Sclerosis
  • Multiple Sclerosis, Relapsing-Remitting
  • Saint Louis, Missouri
  • +4 more
Jan 4, 2023

Mechanistic Studies of Teriflunomide in RRMS

Active, not recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Ann Arbor, Michigan
    University of Michigan
Jul 27, 2022

Assess New Participant's Perspectives Beyond Clinical Efficacy

Not yet recruiting
  • Multiple Sclerosis, Relapsing-Remitting
    • (no location specified)
    Nov 7, 2023

    Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis Trial in France (Perfusion of treatment Rituximab, Perfusion of

    Not yet recruiting
    • Multiple Sclerosis
    • Relapsing-remitting Multiple Sclerosis
    • Perfusion of treatment Rituximab
    • Perfusion of treatment Ocrelizumab
    • Lyon, Bron, France
    • +22 more
    Mar 6, 2023

    Bafiertam Treatment In Routine Clinical Practice

    Enrolling by invitation
    • Relapsing Remitting Multiple Sclerosis
    • Monomethyl Fumarate
    • West Hollywood, California
    • +1 more
    Aug 3, 2023

    Describe Switching FromFirst- or Second-line Disease Modifying

    Not yet recruiting
    • Multiple Sclerosis, Relapsing-Remitting
      • (no location specified)
      Dec 12, 2022

      Multiple Sclerosis Trial in Genova (7-day Fasting-Mimicking Diet (7-DAY FMD))

      Active, not recruiting
      • Multiple Sclerosis
      • 7-day Fasting-Mimicking Diet (7-DAY FMD)
      • Genova, Italy
        Ospedale San Martino
      Sep 8, 2023

      Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

      Not yet recruiting
      • Relapsing-remitting Multiple Sclerosis (RRMS)
        • (no location specified)
        Apr 11, 2023

        Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Trial in Tokyo (OCH-NCNP1, Placebo)

        Active, not recruiting
        • Multiple Sclerosis, Relapsing-Remitting
        • Multiple Sclerosis, Secondary Progressive
        • Tokyo, Japan
          National Center of Neurology and Psychiatry
        Sep 28, 2022

        Multiple Sclerosis Trial in Amsterdam (MS Sherpa)

        Recruiting
        • Multiple Sclerosis
        • MS Sherpa
        • Amsterdam, Netherlands
          Amsterdam UMC, locatie VUmc
        Nov 4, 2023

        Multiple Sclerosis, Relapsing-Remitting Trial in Switzerland (serum Neurofilament Filament Light chain (sNfL) monitoring)

        Not yet recruiting
        • Multiple Sclerosis, Relapsing-Remitting
        • serum Neurofilament Filament Light chain (sNfL) monitoring
        • Basel, Basel Stadt, Switzerland
        • +7 more
        Oct 17, 2023

        Multiple Sclerosis, Relapsing-Remitting, Caloric Restriction Trial in Pozzilli (Caloric restriction, Caloric restriction without

        Recruiting
        • Multiple Sclerosis, Relapsing-Remitting
        • Caloric Restriction
        • Caloric restriction
        • Caloric restriction without cow's milk and gluten
        • Pozzilli, IS, Italy
          Neuromed - Istituto Neurologico Mediterraneo Pozzilli
        Jul 26, 2022

        Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive Trial in Cleveland (Cionic

        Recruiting
        • Multiple Sclerosis
        • +2 more
        • Cionic Neural Sleeve NS-100
        • Actigraph accelerometer
        • Cleveland, Ohio
          Cleveland State University
        Jul 25, 2023

        Assess Resource Utilization and Quality of Life of RRMS Treated

        Completed
        • RRMS
        • Dimethyl Fumarate (DMF)
        • Thessaloniki, Greece
          University General Hospital AHEPA (B')
        Jul 27, 2021

        Multiple Sclerosis (MS) Trial in Canada, United States (elezanumab, )

        Completed
        • Multiple Sclerosis (MS)
        • Birmingham, Alabama
        • +48 more
        Dec 1, 2021

        Lesion Load and Location in Relation to Cognition, Fatigue and

        Completed
        • Relapsing Remitting Multiple Sclerosis
        • VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures)
        • Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
        • Assiut, Egypt
          Eman Khedr
        Oct 27, 2022

        Multiple Sclerosis, Relapsing-Remitting Trial in Porto Alegre (Cladribine 10 mg oral tablet)

        Active, not recruiting
        • Multiple Sclerosis, Relapsing-Remitting
        • Cladribine 10 mg oral tablet
        • Porto Alegre, RS, Brazil
          Pontifical Catholic University of Rio Grande do Sul
        Jun 5, 2023

        Cardiometabolic Health in Multiple Sclerosis

        Recruiting
        • Multiple Sclerosis, Relapsing-Remitting
          • Diepenbeek, Limburg, Belgium
            Hasselt University
          Mar 1, 2023

          Ofatumumab in Portuguese Multiple Sclerosis Patients

          Not yet recruiting
          • Relapsing Multiple Sclerosis
          • Ofatumumab
          • (no location specified)
          Mar 30, 2023